|
GNPAT expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.85140003328144E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.54659998538887E-09 |
| Normal-vs-Stage2 |
2.4332999999932E-05 |
| Normal-vs-Stage3 |
5.25690000419132E-08 |
| Normal-vs-Stage4 |
1.60710999999036E-05 |
| Stage1-vs-Stage2 |
6.602000E-01 |
| Stage1-vs-Stage3 |
5.925600E-01 |
| Stage1-vs-Stage4 |
9.678400E-01 |
| Stage2-vs-Stage3 |
4.603800E-01 |
| Stage2-vs-Stage4 |
7.354800E-01 |
| Stage3-vs-Stage4 |
6.950000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.96840021849232E-10 |
| Normal-vs-AfricanAmerican |
1.512210E-01 |
| Normal-vs-Asian |
1.93209999999056E-06 |
| Caucasian-vs-AfricanAmerican |
3.534300E-02 |
| Caucasian-vs-Asian |
6.783600E-01 |
| AfricanAmerican-vs-Asian |
1.257000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.85389999998831E-06 |
| Normal-vs-Female |
2.89979995571343E-09 |
| Male-vs-Female |
3.023800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.01449999956316E-07 |
| Normal-vs-Age(41-60Yrs) |
3.26420002139116E-09 |
| Normal-vs-Age(61-80Yrs) |
1.988000E-04 |
| Normal-vs-Age(81-100Yrs) |
1.830150E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.629400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.189400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.169400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.961900E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.662400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.635600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.951200E-01 |
| Classical-VS-Follicular |
6.410400E-01 |
| Classical-VS-Other |
8.917000E-01 |
| Classical-VS-Normal |
6.17089999987996E-07 |
| Tall-VS-Follicular |
4.898000E-01 |
| Tall-VS-Other |
5.019000E-01 |
| Tall-VS-Normal |
4.16240000000734E-06 |
| Follicular-VS-Other |
7.742000E-01 |
| Follicular-VS-Normal |
2.05269999997704E-06 |
| Other-VS-Normal |
4.075800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.05580000298033E-08 |
| Normal-vs-N1 |
2.45679998567283E-09 |
| N0-vs-N1 |
1.782750E-01 |
|
|
